| Literature DB >> 32784482 |
Eva Bianconi1, Raffaella Casadei2, Flavia Frabetti3, Carlo Ventura1,3, Federica Facchin1,3, Silvia Canaider1,3.
Abstract
In humans, sexual dimorphism can manifest in many ways and it is widely studied in several knowledge fields. It is increasing the evidence that also cells differ according to sex, a correlation still little studied and poorly considered when cells are used in scientific research. Specifically, our interest is on the sex-related dimorphism on the human mesenchymal stem cells (hMSCs) transcriptome. A systematic meta-analysis of hMSC microarrays was performed by using the Transcriptome Mapper (TRAM) software. This bioinformatic tool was used to integrate and normalize datasets from multiple sources and allowed us to highlight chromosomal segments and genes differently expressed in hMSCs derived from adipose tissue (hADSCs) of male and female donors. Chromosomal segments and differentially expressed genes in male and female hADSCs resulted to be related to several processes as inflammation, adipogenic and neurogenic differentiation and cell communication. Obtained results lead us to hypothesize that the donor sex of hADSCs is a variable influencing a wide range of stem cell biologic processes. We believe that it should be considered in biologic research and stem cell therapy.Entities:
Keywords: gene expression; human adipose derived stem cells; mesenchymal stem cells; microarray; sex; sex dimorphism
Mesh:
Year: 2020 PMID: 32784482 PMCID: PMC7464371 DOI: 10.3390/genes11080909
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Flow diagram of data searching and selection strategy for Transcriptome Mapper (TRAM) meta-analysis.
Main features of the samples selected for the meta-analyses with TRAM software.
| GEO Series | GEO Platform ID | Sex | Samples | Age | Regional Depot | Pool | PMID |
|---|---|---|---|---|---|---|---|
| GSE8954 | GPL201 | M | GSM226880 | 40.2 ± 14.2 | Abdomen | A | 20849362 [ |
| M | GSM226881 | 40.2 ± 14.2 | A | ||||
| F | GSM226882 | 40.2 ± 14.2 | B (D) | ||||
| F | GSM226883 | 40.2 ± 14.2 | B (D) | ||||
| GSE12399 | GPL201 | M | GSM311246 | 52 | Abdomen | A | N/A |
| F | GSM311250 | 42 | B (C) | ||||
| GSE18201 | GPL201 | F | GSM455150 | 42 | Abdomen | B (C) | 20605541 [ |
| M | GSM455151 | 49 | A | ||||
| F | GSM455152 | 51 | B (C) | ||||
| GSE19773 | GPL7363 | F | GSM493884 | (18–39) | Abdomen | B (D) | 20410135 [ |
| F | GSM493885 | (18–39) | B (D) | ||||
| GSE24433 | GPL571 | F | GSM602158 | Adult | Abdomen | B (D) | 22669576 [ |
| GSE37324 | GPL6244 | F | GSM916113 | 69 | Abdomen | B (C) | 23526958 [ |
| F | GSM916114 | 69 | B (C) | ||||
| F | GSM916116 | 69 | B (C) | ||||
| M | GSM916117 | 71 | A | ||||
| M | GSM916119 | 71 | A | ||||
| M | GSM916123 | 71 | A | ||||
| F | GSM916124 | 62 | B (C) | ||||
| F | GSM916128 | 62 | B (C) | ||||
| M | GSM916129 | 53 | A | ||||
| F | GSM916130 | 62 | B (C) | ||||
| M | GSM916132 | 56 | A | ||||
| M | GSM916135 | 53 | A | ||||
| M | GSM916136 | 53 | A | ||||
| GSE48220 | GPL6480 | F | GSM1173058 | 39 | N/A* | B (D) | N/A |
| F | GSM1173059 | 31 | B (D) | ||||
| F | GSM1173060 | 35 | B (D) | ||||
| F | GSM1173061 | 32 | B (D) | ||||
| F | GSM1173062 | 29 | B (D) | ||||
| F | GSM1173063 | 37 | B (D) | ||||
| GSE48774 | GPL6884 | F | GSM1184376 | (24–40) | Thigh/buttock | B (D) | 26462465 [ |
| F | GSM1184377 | (24–40) | B (D) | ||||
| F | GSM1184378 | (24–40) | B (D) | ||||
| GSE57538 | GPL13158 | F | GSM1384338 | (36–45) | Abdomen | B (D) | 25437437 [ |
| F | GSM1384339 | (36–45) | B (D) | ||||
| F | GSM1384340 | (36–45) | B (D) | ||||
| GSE77272 | GPL10558 | M | GSM2047165 | 31 | Abdomen | A | 27224250 [ |
| F | GSM2047164 | 56 | B (D) | ||||
| F | GSM2047166 | 19 | B (D) | ||||
| F | GSM2047167 | 57 | B (D) | ||||
| GSE98421 | GPL570 | F | GSM2595136 | 30 | Abdomen | B (D) | N/A |
| F | GSM2595137 | 19 | B (D) | ||||
| F | GSM2595138 | 29 | B (D) | ||||
| F | GSM2595139 | 33 | B (D) |
Gene Expression Omnibus (GEO) series and platform ID—ID numbers as stated in the GEO database; Sex—male (M) and female (F) hADSC donor samples; Samples—sample named as stated in the GEO database; Age—donor age declared in GEO series or in related manuscript as the specific/range age or as the mean value of all the indicated donors’ ages and standard deviation (SD); Adult—subject >18 years old; Pool—in order to perform the described analyses all samples were divided into pools (see “Materials and Methods” Section; “TRAM analysis” paragraph); PMID—PubMed identifier number of the reference reported in the GEO database; N/A—information not available; *—female liposuction.
Chromosomal segments statistically significant in TRAM “Map” mode analysis of male vs. female hMSCs derived from adipose tissue (hADSCs) samples.
| Chr | Location | Segment Start | Segment End | Expression Ratio | Genes in the Segment | |
|---|---|---|---|---|---|---|
| Chr 4 | 4p12-p11 | 48,250,001 | 48,750,000 | 2.38 | 1.73 × 10−4 | |
| Chr22 | 22q11.22 | 22,750,001 | 23,250,000 | 2.34 | 1.70 × 10−4 | |
| Chr7 | 7q21.3 | 93,500,001 | 94,000,000 | 0.50 | 8.67 × 10−5 |
Statistically significant segments obtained with TRAM “Map” mode analysis (default parameters) by comparing pool A (male derived hADSCs) vs. pool B (female derived hADSCs). The resulted segments are sorted by decreasing the expression ratio. Chr—chromosome; Location—segment cytoband derived from the first mapped gene within the segment; segment start/end—chromosomal coordinates for each segment; Genes in the segment—bold and +—overexpressed gene; bold and −—underexpressed gene; ‘+’ or ‘−’—gene expression value higher or lower than the median value; respectively.
List of the twenty genes significantly most over- or underexpressed (all significantly, with q < 0.05) in male vs. female hADSC samples.
| Gene Name | Gene ID | Function (GO Terms) | Chr | Location | Segment Start | Segment End | Expression Ratio |
|---|---|---|---|---|---|---|---|
|
| 3696 | extracellular matrix protein binding | Chr7 | 7p21.1 | 20,318,751 | 20,425,000 | 8.88 |
|
| 8561 | metal ion binding | Chr10 | 10p13 | 15,506,251 | 15,731,250 | 6.89 |
|
| 117248 | carbohydrate binding | Chr3 | 3p25.1 | 16,162,501 | 16,256,250 | 5.93 |
|
| 3690 | extracellular matrix protein binding | Chr17 | 17q21.32 | 47,243,751 | 47,256,250 | 5.97 |
|
| 25992 | Notch binding | Chr2 | 2q37.3 | 240,987,501 | 241,068,750 | 5.68 |
|
| 23365 | G protein-coupled receptor binding | Chr11 | 11q23.3 | 120,337,501 | 120,500,000 | 5.51 |
|
| 23264 | RNA binding | Chr22 | 22q13.2 | 41,306,251 | 41,362,500 | 5.42 |
|
| 84162 | protein binding | Chr4 | 4q27 | 122,143,751 | 122,375,000 | 5.27 |
|
| 143686 | protein binding | Chr11 | 11q21 | 95,231,251 | 95,243,750 | 5.23 |
|
| 50937 | protein binding | Chr11 | 11q24.2 | 125,950,001 | 126,075,000 | 5.04 |
|
| 119587 | zinc ion binding | Chr10 | 10q26.13 | 123,737,501 | 123,956,250 | 4.97 |
|
| 57674 | ATPase activity | Chr17 | 17q25.3 | 80,256,251 | 80,350,000 | 4.96 |
|
| 3113 | peptide antigen binding | Chr6 | 6p21.32 | 33,056,251 | 33,075,000 | 4.89 |
|
| 79689 | FAD binding | Chr7 | 7q21.12 | 88,268,751 | 88,318,750 | 4.79 |
|
| 378938 |
| Chr11 | 11q13.1 | 65,487,501 | 65,512,500 | 4.72 |
|
| 7148 | collagen fibril binding | Chr6 | 6p21.33-p21.32 | 32,043,751 | 32,106,250 | 4.68 |
|
| 1435 | cytokine activity | Chr1 | 1p13.3 | 109,900,001 | 109,937,500 | 4.64 |
|
| 286223 |
| Chr9 | 9q22.1 | 88,981,251 | 89,000,000 | 4.55 |
|
| 405 | DNA-binding transcription factor activity | Chr1 | 1q21.3 | 150,812,501 | 150,887,500 | 4.49 |
|
| 642273 | α-tubulin binding | Chr2 | 2p25.3 | 31,251 | 56,250 | 4.46 |
|
| 27254 | transcription factor binding | Chr11 | 11p15.1 | 18,256,251 | 18,268,750 | 0.14 |
|
| 27254 | transcription factor binding | Chr22 | 22q13.2 | 41,550,001 | 41,575,000 | 0.14 |
|
| 5800 | protein binding | Chr12 | 12p13-p12 | 15,593,751 | 15,606,250 | 0.14 |
|
| 255239 | ATP binding | Chr11 | 11q23.2 | 113,387,501 | 113,406,250 | 0.13 |
|
| 339665 | antiporter activity | Chr22 | 22q12.2 | 30,631,251 | 30,681,250 | 0.12 |
|
| 23261 | sequence-specific DNA binding | Chr1 | 1p36.31-p36.23 | 6,775,001 | 7,768,750 | 0.11 |
|
| 144983 | RNA binding | Chr13 | 13q14.3 | 52,606,251 | 52,650,000 | 0.11 |
|
| 2921 | chemokine activity | Chr1 | 1q32.1 | 74,025,001 | 206,900,000 | 0.11 |
|
| 92259 | structural constituent of ribosome | Chr5 | 5q13.2 | 69,212,501 | 69,231,250 | 0.10 |
|
| 4496 | metal ion binding | Chr16 | 16q13 | 56,668,751 | 56,681,250 | 0.10 |
|
| 23120 | ATP binding | Chr5 | 5q34 | 160,556,251 | 160,937,500 | 0.10 |
|
| 4490 | metal ion binding | Chr16 | 16q13 | 56,643,751 | 56,656,250 | 0.07 |
|
| 200916 | RNA binding | Chr3 | 3q26.2 | 170,856,251 | 170,881,250 | 0.08 |
|
| 140801 | structural constituent of ribosome | Chr14 | 14q21.2 | 46,643,751 | 46,662,500 | 0.08 |
|
| 497661 | protein binding | Chr18 | 18q21.1 | 49,468,751 | 49,487,500 | 0.07 |
|
| 7381 | protein binding | Chr8 | 8q22.1 | 96,218,751 | 96,237,500 | 0.06 |
|
| 387990 | mitochondrion targeting sequence binding | Chr14 | 14q23.1 | 58,387,501 | 58,406,250 | 0.06 |
|
| 144568 | endopeptidase inhibitor activity | Chr12 | 12p13.31 | 8,812,501 | 8,893,750 | 0.06 |
|
| 645745 | metal ion binding | Chr1 | 1q43 | 236,993,751 | 237,012,500 | 0.05 |
|
| 23117 | molecular function | Chr16 | 16p12.2 | 21,393,751 | 21,437,500 | 0.02 |
TRAM “Map” mode analysis (single gene level parameters) comparing pool A (male derived hADSCs) vs. pool B (female derived hADSCs). The list is referred to the twenty most over- and underexpressed genes resulted with a segment window of 12,500 bp, considering genome median analysis (see full results in Supplementary Information section). Genes are sorted by decreasing the expression ratio. Gene ID—gene identification number in gene NCBHI; Chr—chromosome; Function—gene ontology function; N/A—information not available; location—segment cytoband derived from the first mapped gene within the segment; segment start/end—chromosomal coordinates for each segment.
Chromosomal segments statistically significant in TRAM “Map” mode analysis of hADSC female samples with fibroblast growth factor (FGF) vs. hADSC female samples without FGF.
| Chr | Location | Segment Start | Segment End | Expression Ratio | Genes in the Segment | |
|---|---|---|---|---|---|---|
| Chr11 | 11p15.5 | 1,250,001 | 1,750,000 | 4.44 | 6.13 × 10−4 | |
| Chr19 | 19q13.33 | 49,250,001 | 49,750,000 | 4.44 | 8.91 × 10−3 | |
| Chr20 | 20q11.23 | 38,000,001 | 38,500,000 | 4.23 | 1.26 × 10−5 | |
| Chr1 | 1q25.1 | 173,750,001 | 174,250,000 | 4.20 | 7.52 × 10−3 | |
| Chr11 | 11p15.5 | 1,500,001 | 2,000,000 | 4.17 | 1.10 × 10−3 | |
| Chr4 | 4p12-p11 | 48,250,001 | 48,750,000 | 3.95 | 5.97 × 10−4 | |
| Chr11 | 11q12.1 | 56,000,001 | 56,500,000 | 0.39 | 1.10 × 10−3 | |
| Chr7 | 7p21.1 | 16,500,001 | 17,000,000 | 0.36 | 2.98 × 10−4 |
Chromosomal segments resulted by “TRAM FGF” “Map” mode analysis (default parameters) by comparing pool C (female hADSCs cultured in a medium enriched by FGF) vs. pool D (female hADSCs cultured in standard medium). The resulted segments are sorted by decreasing the expression ratio. chr—chromosome; location—segment cytoband derived from the first mapped gene within the segment; segment start/end—chromosomal coordinates for each segment; genes in the segment—bold and +—overexpressed gene; bold and −—underexpressed gene; ‘+’ or ‘−’—gene expression value higher or lower than the median value, respectively.
Figure 2Venn diagram of the 40 most significantly regulated genes obtained with “TRAM sex” and “TRAM FGF” single gene level analysis. Genes in bold are those overexpressed in male (diagram “SEX”) or in cell supplemented with FGF (diagram “FGF”), while genes written not in bold are the underexpressed ones.